Holen Sie sich die Stockscreener-App
42.12
3.55%
1.445
Handel nachbörslich:
42.15
0.025
+0.06%
Schlusskurs vom Vortag:
$40.68
Offen:
$40.81
24-Stunden-Volumen:
312.70K
Relative Volume:
0.87
Marktkapitalisierung:
$2.01B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-107.28M
KGV:
-16.18
EPS:
-2.6031
Netto-Cashflow:
$-80.71M
1W Leistung:
+4.76%
1M Leistung:
+5.15%
6M Leistung:
+53.85%
1J Leistung:
+162.46%
1-Tages-Spanne:
$40.81
$43.02
1-Wochen-Bereich:
$39.93
$43.29
52-Wochen-Spanne:
$13.62
$44.28
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Firmenname
Rapport Therapeutics Inc
Sektor
Branche
Telefon
857-321-8020
Adresse
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
42.12 | 1.95B | 0 | -107.28M | -80.71M | -2.6031 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Strong Buy |
| 2026-02-02 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-09-16 | Eingeleitet | Truist | Buy |
| 2025-08-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-08 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Eingeleitet | Jefferies | Buy |
| 2024-07-02 | Eingeleitet | Stifel | Buy |
| 2024-07-02 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Rapport Therapeutics Inc Aktie (RAPP) Neueste Nachrichten
William Blair initiates Rapport Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Rapport Therapeutics Inc (RAPP) Institutional Confidence - TradingKey
RAPP|Rapport Therapeutics Inc|Price:40.680|Chg%:-0.700 - TradingKey
RAPP|Rapport Therapeutics Inc|Price:41.780|Chg%:+1.100 - TradingKey
Rapport Therapeutics Inc (RAPP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rapport Therapeutics Inc (RAPP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rapport Therapeutics Inc (RAPP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rapport Therapeutics Inc (RAPP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Rapport Therapeutics Inc (RAPP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Price to earnings forward of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
Price to sales forward of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring a 37% Potential Upside in CNS Therapeutics - DirectorsTalk Interviews
Responsive Playbooks and the RAPP Inflection - Stock Traders Daily
Goldman Sachs Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Raises Target Price to $58 - Moomoo
Enterprise value to EBITDA forward of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
Analysts Offer Insights on NA Companies: Solv Energy (Nasdaq: MWH), Rapport Therapeutics, Inc. (RAPP) and Volvo Car AB Class B (OtherVLVOF) - The Globe and Mail
Rapport Therapeutics (RAPP) Q1 2026 earnings summary - Quartr
TD Cowen Maintains Rapport Therapeutics(RAPP.US) With Buy Rating - Moomoo
RAP-219’s Differentiated Mechanism Supports Unchanged $65 Price Target and Reiterated Buy on Rapport Therapeutics - TipRanks
RAPP Reiterates by BTIG -- Price Target Maintained at $65.00 - GuruFocus
Rapport Therapeutics CEO Ceesay Abraham sells $328,436 in stock By Investing.com - Investing.com Nigeria
Form 4 Rapport Therapeutics Inc For: 15 July By Investing.com - Investing.com Nigeria
Rapport Therapeutics CEO Ceesay Abraham sells $328,436 in stock - Investing.com
Rapport Therapeutics (RAPP) Slips 1.85%, Approaching Key Support at $38.66Bullish Percent Index - dars.gov.et
Enterprise value to revenue forward of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
Enterprise value to EBIT forward of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors? - Yahoo Finance
Rapport Therapeutics (RAPP) Stifel 2026 Virtual CNS Forum Summary - Quartr
Rapport Therapeutics (RAPP) TD Cowen 45th Annual Healthcare Conference Summary - Quartr
Rapport Therapeutics (RAPP) Jefferies Global Healthcare Conference 2026 Summary - Quartr
We're Not Very Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn Rate - Moomoo
How Broad Russell Index Additions At Rapport Therapeutics (RAPP) Have Changed Its Investment Story - simplywall.st
RAPPRapport Therapeutics Inc Short Interest - Finviz
Rapport Therapeutics Hits New 52-Week High of $43.65 - MarketsMojo
Insider Sell: Cheryl Gault Sells 10,000 Shares of Rapport Therap - GuruFocus
Understanding the Setup: (RAPP) and Scalable Risk - Stock Traders Daily
Rapport Therapeutics (RAPP) COO sells 10,000 shares in pre-set 10b5-1 trades - Stock Titan
Rapport Therapeutics (RAPP) CEO sells 8,220 shares under Rule 10b5-1 plans - Stock Titan
Rapport Therapeutics (RAPP) Declines 2.3% as Shares Approach Key SupportETF Liquidity - dars.gov.et
[144] Rapport Therapeutics, Inc. SEC Filing - Stock Titan
Rapport Therapeutics stock hits all-time high at 42.36 USD By Investing.com - Investing.com Nigeria
Rapport Therapeutics stock hits all-time high at 42.36 USD - Investing.com
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 2500 Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 2000 Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 3000E Growth Benchmark - marketscreener.com
Rapport Therapeutics (RAPP) Stifel 2025 Healthcare Conference Summary - Quartr
Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 3000 Growth Benchmark - marketscreener.com
Rapport Therapeutics, Inc. Actuals & Estimates (NASDAQ:RAPP) - TradingView
Finanzdaten der Rapport Therapeutics Inc-Aktie (RAPP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):